Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 9 » Issue 1

Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies

Authors Ferguson G, Feldman G, Hofbauer P, Hamilton A, Allen L, Korducki L, Sachs P

Received 7 February 2014

Accepted for publication 2 May 2014

Published 16 June 2014 Volume 2014:9(1) Pages 629—645


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Gary T Ferguson,1 Gregory J Feldman,2 Peter Hofbauer,3 Alan Hamilton,4 Lisa Allen,5 Lawrence Korducki,5 Paul Sachs6

1Pulmonary Research Institute of Southeast Michigan, Livonia, MI, 2S Carolina Pharmaceutical Research, Spartanburg, SC, USA; 3Pneumologie, Weinheim, Germany; 4Boehringer Ingelheim, Burlington, ON, Canada; 5Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, 6Pulmonary Associates of Stamford, Stamford, CT, USA

Background: Olodaterol is a long-acting β2-agonist with a 24-hour bronchodilator profile. Two replicate, randomized, double-blind, placebo-controlled, parallel-group, Phase III trials were performed as part of a comprehensive clinical program to investigate the long-term safety and efficacy of olodaterol in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) receiving usual-care background therapy.
Methods: Patients received olodaterol 5 µg or 10 µg or placebo once daily for 48 weeks. Coprimary end points were forced expiratory volume in 1 second (FEV1) area under the curve from 0 to 3 hours (AUC0–3) response (change from baseline), and trough FEV1 response at 12 weeks. Secondary end points included additional lung function assessments, use of rescue medications, FEV1 AUC response from 0 to 12 hours, and Patient Global Rating over 48 weeks.
Results: Overall, 624 and 642 patients were evaluated in studies 1222.11 and 1222.12, respectively. In both studies, olodaterol 5 µg and 10 µg significantly improved the FEV1 AUC0–3 response (P<0.0001) and trough FEV1 (study 1222.11, P<0.0001; study 1222.12, P<0.05, post hoc) at week 12, with an incidence of adverse events comparable with that of placebo. Secondary end points supported the efficacy of olodaterol.
Conclusion: These studies demonstrate the long-term efficacy and safety of once-daily olodaterol 5 µg and 10 µg in patients with moderate to very severe COPD continuing with usual-care maintenance therapy.

Keywords: chronic obstructive pulmonary disease, bronchodilator, olodaterol

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Other articles by this author:

Readers of this article also read:

Inhibition of heat-shock protein 90 sensitizes liver cancer stem-like cells to magnetic hyperthermia and enhances anti-tumor effect on hepatocellular carcinoma-burdened nude mice

Yang R, Tang QS, Miao FQ, An YL, Li MF, Han Y, Wang XH, Wang J, Liu PD, Chen R

International Journal of Nanomedicine 2015, 10:7345-7358

Published Date: 7 December 2015

Probing insulin bioactivity in oral nanoparticles produced by ultrasonication-assisted emulsification/internal gelation

Lopes MA, Abrahim-Vieira B, Oliveira C, Fonte P, Souza AMT, Lira T, Sequeira JAD, Rodrigues CR, Cabral LM, Sarmento B, Seiça R, Veiga F, Ribeiro AJ

International Journal of Nanomedicine 2015, 10:5865-5880

Published Date: 18 September 2015

Nanolayer formation on titanium by phosphonated gelatin for cell adhesion and growth enhancement

Zhou X, Park SH, Mao H, Isoshima T, Wang Y, Ito Y

International Journal of Nanomedicine 2015, 10:5597-5607

Published Date: 2 September 2015

pH-Responsive therapeutic solid lipid nanoparticles for reducing P-glycoprotein-mediated drug efflux of multidrug resistant cancer cells

Chen HH, Huang WC, Chiang WH, Liu TI, Shen MY, Hsu YH, Lin SC, Chiu HC

International Journal of Nanomedicine 2015, 10:5035-5048

Published Date: 5 August 2015

Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients

De Backer J, Vos W, Van Holsbeke C, Vinchurkar S, Claes R, Parizel PM, De Backer W

International Journal of Chronic Obstructive Pulmonary Disease 2013, 8:569-579

Published Date: 22 November 2013